ATF6 and achromatopsia: In patients with achromatopsia caused by ATF6, a clinical trial (NCT04041232) has been registered to investigate whether the already approved FDA drug, glycerol phenylbutyrate (PBA), which is a fatty acid compound that facilitates protein folding, can improve retinal function.